Researchers finally quantified the hair loss risk that GLP-1 drug users have been reporting for two years, and found it is 37 to 68 percent higher than on comparable medications

GLP-1 receptor agonists have become some of the most prescribed medications in the world in a remarkably short period. Ozempic and Wegovy, both versions of semaglutide, have reshaped how medicine approaches type 2 diabetes and obesity. Mounjaro and Zepbound, both versions of tirzepatide, have followed with results that in some studies surpass even semaglutide for weight loss. The clinical benefits are real and in many cases substantial: improved blood sugar control, significant weight reduction, lower cardiovascular event rates, and reductions in kidney disease progression. For many patients, these drugs have been genuinely transformative.

The side effect profile has been mostly well-characterized: nausea, vomiting, diarrhea, and constipation in the early weeks are the most common complaints. Rarer concerns, including a possible link to thyroid tumors, a condition called gastroparesis, and reports of suicidal ideation, have attracted regulatory scrutiny. But one complaint has been accumulating in online patient communities, in doctor’s offices, and in FDA adverse event reports for the past two years without a large, rigorous study to quantify it: hair loss.

A study published in The BMJ by researchers at the University of Pennsylvania has now produced that quantification. Across nearly 40,000 patients with type 2 diabetes, people taking GLP-1 drugs were significantly more likely to develop diagnosed hair loss than people on two other commonly used classes of diabetes medication. The relative risk was 37 percent higher compared to one drug class and 68 percent higher compared to another. The FDA has already indicated it is evaluating the signal.

How the study was designed

The core methodological challenge in studying drug side effects in real-world patients is confounding: people who take different medications differ from each other in ways that can independently affect the outcome being measured. A study that simply compares hair loss rates between GLP-1 users and the general population would be misleading, because GLP-1 users tend to be heavier, have worse metabolic health, and may be losing weight rapidly, all of which could independently contribute to hair loss regardless of the drug itself.

The Penn team addressed this by choosing comparison groups that were as similar as possible to GLP-1 users at baseline. Rather than comparing against the general population, they compared GLP-1 users against people taking SGLT-2 inhibitors and DPP-4 inhibitors, two other classes of diabetes medication. Patients starting any of these drugs for the same underlying condition tend to look similar at baseline in terms of age, disease severity, and health profile, making them a much more appropriate comparison than the general population would be.

The researchers then used statistical methods, specifically propensity score matching, to further balance the comparison groups on variables like age, sex, ethnicity, body mass index, and pre-existing conditions that could independently affect hair loss risk. After this balancing, the remaining difference in hair loss rates between groups is more likely to reflect a genuine drug effect.

The dataset came from the University of Pennsylvania Health System’s electronic health records. The final analysis compared 12,004 GLP-1 users against 15,221 SGLT-2 inhibitor users, and an additional 11,964 GLP-1 users against 11,233 DPP-4 inhibitor users, for a total of nearly 40,000 patients.

What the numbers show

After accounting for baseline differences, GLP-1 drug users were 37 percent more likely to receive a hair loss diagnosis than SGLT-2 inhibitor users during the follow-up period. Compared to DPP-4 inhibitor users, the increased risk was 68 percent.

These relative risk numbers require context to interpret correctly. The absolute risk of hair loss on GLP-1 drugs was approximately 7 cases per 1,000 patients per year, compared to roughly 4 to 5 cases per 1,000 patients per year on the comparator drugs. The difference in absolute terms is therefore small: roughly 2 to 3 additional hair loss cases per 1,000 patients per year. For an individual patient, the probability of developing hair loss remains low. For a population in which tens of millions of people are taking these drugs, even a small per-patient probability translates into a meaningful number of affected individuals.

The timing pattern was also informative. Most diagnosed hair loss cases clustered in the months just before the one-year mark, suggesting that the risk is concentrated in the period of most rapid weight loss and physiological adjustment rather than being evenly distributed across the entire treatment period. Whether hair loss risk diminishes after the first year, as the body stabilizes at its new weight, is a question the study’s follow-up window cannot definitively answer.

Why GLP-1 drugs might cause hair loss

The biological mechanism behind the association remains unknown, and the study was not designed to answer this question. The authors propose three plausible explanations, each supported by some indirect evidence but none yet confirmed.

The first is rapid weight loss itself. Dramatic and rapid reductions in caloric intake and body weight are a known trigger for a condition called telogen effluvium, in which a large proportion of hair follicles simultaneously enter the resting phase of the growth cycle and then shed synchronously several months later. This condition is well-documented following bariatric surgery, another intervention that produces rapid weight loss, and the timing of hair loss after GLP-1 initiation, clustering near the one-year mark when weight loss is often most pronounced, is consistent with this mechanism.

The second possibility is a direct pharmacological effect of GLP-1 receptor activation on hair follicle biology. GLP-1 receptors are expressed in multiple tissues throughout the body, and some preliminary research has suggested that GLP-1 signaling may influence hair follicle cycling. If the drug itself directly affects follicle behavior independently of weight loss, patients who are not losing significant weight might still be at risk, which would have implications for how the side effect is understood and managed.

The third possibility involves the hormonal and nutritional changes that accompany significant weight loss, including changes in thyroid function, zinc, biotin, and other micronutrients that influence hair growth. Caloric restriction sufficient to produce rapid weight loss can deplete the nutritional substrates that hair follicles require to maintain normal growth cycling.

Distinguishing between these mechanisms matters for management. If the cause is primarily rapid weight loss, slowing the rate of weight reduction might mitigate the risk. If the cause is a direct drug effect, changing the dose or switching to a different GLP-1 agent might help. If nutritional deficiency is the primary driver, supplementation could be relevant. None of these management strategies has been evaluated in clinical trials.

What regulators already know

The FDA has not been unaware of this potential signal. The study notes that the agency has indicated it is evaluating reports of hair loss in connection with GLP-1 drugs, particularly semaglutide and tirzepatide. The UK’s Medicines and Healthcare products Regulatory Agency had received 399 reports of hair loss relating to tirzepatide and 541 the previous year, along with 148 reports relating to semaglutide. These spontaneous reports from healthcare providers and patients were the first signals that a pattern might exist. The Penn study is the first large comparative analysis using rigorous epidemiological methods to put numbers behind those reports.

The authors note that some regulatory bodies have already updated prescribing information to note hair loss as a potential adverse effect. The BMJ study is likely to accelerate regulatory review in jurisdictions where that has not yet occurred.

What patients taking these drugs should know

The clinical message the researchers offer is measured. “Although the absolute risk is low, awareness of this potential effect may help to inform treatment decisions,” they write. For the vast majority of people taking GLP-1 drugs, the substantial metabolic benefits of these medications, including weight reduction, improved blood sugar control, and reduced cardiovascular risk, will outweigh the small increased probability of a hair loss diagnosis.

But for patients who are already experiencing hair thinning from other causes, or for whom hair loss would be particularly distressing, the new information adds a relevant consideration to the conversation with their prescribing physician. And for patients who notice hair shedding in the first year of treatment, the study provides reassurance of a kind: the pattern of clustering near the one-year mark suggests that for many patients the effect may be time-limited rather than permanent, consistent with the natural history of telogen effluvium triggered by rapid weight loss.

The study’s findings also apply, at this stage, only to people taking GLP-1 drugs for type 2 diabetes. The much larger and rapidly growing population taking semaglutide and tirzepatide purely for weight loss, without a diabetes diagnosis, was not captured in this dataset. Whether the same risk pattern holds in that population, which is the majority of GLP-1 users in many countries, remains to be established in future research. GLP-1 drugs used for weight loss may involve higher doses, faster weight loss trajectories, and different baseline health profiles than the diabetes population studied here, all of which could affect the magnitude and timing of hair loss risk.

Source

Yiyi Tang, Jalpa A. Doshi, Christopher B. Forrest et al. “Risk of hair loss associated with glucagon-like peptide 1 receptor agonists: population based cohort study.” The BMJ, 2026.
DOI: 10.1136/bmj-2026-085522